Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern

Intellia tanks as it pauses late-stage CRISPR gene-editing trials after one patient was hospitalized

Intellia had also disclosed in May that a patient had experienced elevated liver enzymes....

Intellia Pauses Gene Therapy Trials After Patient Hospitalized

Intellia Therapeutics Inc. paused clinical trials for its gene editing treatments after a patient was hospitalized with liver damage, a setback as it seeks to sell the first one-time treatment for heart and nerve conditions.

Intellia plummets following severe adverse event in phase 3 nex-z trial

Intellia Therapeutics halts dosing in two phase 3 trials after patient safety concerns, impacting shares. Read more here.

Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern

The company has previously encountered few serious safety concerns, despite dosing hundreds of patients across its clinical trials.

Intellia pauses two CRISPR trials after liver toxicity hospitalizes patient

Intellia Therapeutics has paused enrollment and dosing in two clinical trials of its CRISPR therapy, called nex-z, for the genetic disease transthyretin amyloidosis (ATTR), the company announced Monday morning. In a call with investors, CEO ...

Intellia Therapeutics Stock Plummets 45% After CRISPR Trial Shock – Can Gene-Editing Hopes Survive?

CRISPR Trial Halt Triggers Sell-Off Intellia’s stock was hammered on Monday after the biotech stunned investors with news of a clinical trial pause. Before the opening bell, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR treatment nexiguran ziclumeran (NTLA-2001) due to a serious adverse event reuters.com. A patient in the Phase 3 MAGNITUDE study – w…